skip to main content

Analisis Pembiayaan COVID-19 di RSUP dr. Kariadi Semarang

*yuliana setyarini  -  RSUP dr. Kariadi Semarang, Indonesia
Chriswardani Suryawati  -  Fakultas Kesehatan Masyarakat, Universitas Diponegoro, Indonesia
Septo Pawelas Arso  -  Fakultas Kesehatan Masyarakat, Universitas Diponegoro, Indonesia

Citation Format:
Abstract

The cost of COVID-19 services can be a burden in itself that can affect hospital budgets. Services for COVID-19 patients at RSUP dr. Kariadi has so far been running well and smoothly, but there is no detailed data and information regarding COVID-19 financing, the process of submitting a COVID-19 financing claim and its implications for finances and services as well as leadership policies at RSUP dr. Kariadi so that activities are needed to analyze the costs of COVID-19. The purpose of the study was to analyze the financing of COVID-19, the process of submitting a claim for COVID-19 and its implications for finance and services as well as leadership policies at RSUP dr. Kariadi. The research approach used in this research is descriptive. Collecting data through document observation and interviews. The sample was selected using simple random sampling and the sample size was using the Slovin formula. The results showed that there was a negative difference of Rp.-1,832,258.63 between the average real cost of COVID-19 services and those claimed for outpatients, and there was a positive difference of Rp.61,695,327.45 for inpatients. The difference is caused by the claim system using cost per day. The biggest real cost component is the cost of laboratory examinations. The process for submitting a COVID-19 claim is in accordance with applicable regulations and all submissions declared eligible and paid. From the results of the Chi-Square test, it can be seen that there is no relationship between age and real costs in inpatient care and vice versa in outpatient care, length of days of treatment affects real costs, there is a relationship between comorbidities and real costs in SL3 and SL2, and there is no the relationship between co-morbidities with real costs in SL1 and outpatient. COVID-19 has caused the number of hospital visits and revenues in general to decline. Hospital leadership implemented several policies in dealing with the implications of COVID-19, including shifting budget posts, controlling services, zoning services, limiting non-COVID-19 patient services, transferring facilities and infrastructure, and optimizing the claim process. The research results are expected to be used as input in policy making and budget planning.

 

Keywords: Financing Analysis, COVID-19

Fulltext View|Download
Keywords: Real Cost, Claimed Cost, COVID-19

Article Metrics:

  1. Bassetti M, Vena A, Giacobbe DR. The novel Chinese coronavirus (2019-nCoV) infections: Challenges for fighting the storm. Eur J Clin Invest. 2020;50(3):1–4
  2. Patria Jati S, Budiyono, Tiyas Budiyanti R, Suhartono, Ginandjar P, Sriatmi A, et al. Cost Estimates Related to COVID-19 Treatment in Indonesia: What Should be Concerned? E3S Web Conf. 2020;202(12012):1–8
  3. Ambarwati W. Pembiayaan Pasien COVID-19 dan Dampak Keuangan terhadap Rumah Sakit yang Melayani Pasien COVID-19 di Indonesia Analisis Periode Maret 2020 – Desember 2020. J Ekon Kesehat Indones. 2021;6(1):23–37
  4. Widiatmoko, D., Sucahya, P. K., Fikri, I. M., Kusuma, D., Latief, K., Nurwahyuni, A. Estimasi Biaya Layanan Kesehatan (Rumah Sakit) dan Human Capital Loss COVID-19 di Indonesia. Webinar 2020. https://www.youtube.com/watch?v=ilncZ3IZ20k&t=43s
  5. Menteri Kesehatan Republik Indonesia. Petunjuk Teknis Klaim Pengganti Biaya Perawatan Pasien Penyakit Infeksi Emerging Tertentu bagi Rumah Sakit yang Menyelenggarakan Pelayanan Coronavirus Diseases 2019 (COVID-19). Kementerian Kesehatan Republik Indonesia, KMK No. HK.01.07/MENKES/238/2020 Jakarta; 2020
  6. Presiden Republik Indonesia. Penetapan Bencana Nonalam Penyebaran Corona Virus Disease 2019 Sebagai Bencana Nasional. Kementerian Sekretariat Negara Republik Indonesia, Keppres No. 12 Tahun 2020 Jakarta; 2020
  7. RSUP dr. Kariadi. Laporan Penanganan Pandemi COVID-19 RSUP dr. Kariadi Semarang. Semarang; 2021
  8. Aulia, D., dkk. Analisis Perbandingan Biaya Langsung (Direct Cost) dan Biaya Tidak Langsung (Indirect Cost) pada Pasien Stroke di Rumah Sakit. Jurnal Ekonomi Kesehatan Indonesia Vol. 2 No. 2. DOI: 10.7454/eki.v2i2.2143
  9. Tobin MJ. 2020. Basing respiratory management of COVID-19 on physiological principles. American Journal of Respiratory and Critical Care Medicine 2020;201(11):1319-1320. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7258630/
  10. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):10–2
  11. González López-Valcárcel B, Vallejo-Torres L. The costs of COVID-19 and the cost-effectiveness of testing. Appl Econ Anal. 2020;29(85):77–89
  12. Menteri Kesehatan Republik Indonesia. Petunjuk Teknis Klaim Penggantian Biaya Pelayanan Pasien Corona Virus Disease 2019 (Covid- 19) Bagi Rumah Sakit Penyelenggara Pelayanan Corona Virus Disease 2019 (Covid- 19). KMK No. HK.01.07/MENKES/446/2020. Kementerian Kesehatan Republik Indonesia Jakarta; 2020
  13. Menteri Kesehatan Republik Indonesia. Tentang petunjuk teknis klaim penggantian biaya pelayanan pasien corona virus disease 2019 (COVID-19). KMK No.HK.01.07/MENKES/4344/2021. Kementerian Kesehatan Republik Indonesia Jakarta; 2021
  14. Agustina, Palu B, Muchlis N. Analisis Biaya Rill dan Tarif INA CBG’s Di Rumah Sakit Umum Bahagia Kota Makassar. J Muslim Community Heal [Internet]. 2020;1(2):13–25. Available from: http://pasca-umi.ac.id/index.php/jmch/article/view/241/253
  15. Dewi NF, Nurdaliani AP. Klaim Dispute Berkas Pasien Rawat Inap Covid-19 di Rumah Sakit Hermina Depok. J Adm Bisnis Terap. 2021;4(59):1–9
  16. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):10–2
  17. Maltezou HC, Giannouchos T V., Pavli A, Tsonou P, Dedoukou X, Tseroni M, et al. Costs associated with COVID-19 in healthcare personnel in Greece: a cost-of-illness analysis. J Hosp Infect [Internet]. 2021;114(1):126–33. Available from: https://doi.org/10.1016/j.jhin.2021.04.018
  18. Giusman R, Nurwahyuni A. Evaluasi Pelayanan Rawat Jalan RS X pada Masa Pandemi Covid-19 melalui Segmenting, Targeting dan Positioning. J Manaj Kesehat Yayasan RSDr Soetomo. 2021;7(1):72–7
  19. Hidayatullah D, Nurwijayanti N, Farida S. Analysis of Factors that Influence Communities in doing Re-Visit to Outpatient Installation of Praya Hospital Central Lombok. J Qual Public Heal. 2020;3(2):292–9
  20. Thomson, S. 2022. How resilient is health financing policy in Europe. https://www-sciencedirect-com.proxy.undip.ac.id/science/article/pii/S0168851021002724
  21. Goodell, J.W. 2020. COVID-19 and finance : agendas for future research. Elsevier. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152896/
  22. Miethke-Morais, A., Cassenote, A., Piva, H., Tokunaga, E., Cabello, V. 2021. COVID-19-related hospital cost-outcome analysis: The impact of clinical and demographic factors. Braz j infect dis. 2021;25(4):101609. https://www.sciencedirect.com/science/article/pii/S1413867021000787?ref=pdf_download&fr=RR-2&rr=71d2030cfc9c354a

Last update:

  1. Proceedings of the International Conference on Economics and Business Studies (ICOEBS-22-2)

    Zalfa Khoirunnisa, Winny Perwithosuci. Advances in Economics, Business and Management Research, 247 , 2024. doi: 10.2991/978-94-6463-204-0_27

Last update: 2024-02-21 17:35:29

No citation recorded.